Meeting of the National Vaccine Advisory Committee, 51536-51537 [2012-20910]
Download as PDF
<![CDATA[
erowe on DSK2VPTVN1PROD with
51536
Federal Register / Vol. 77, No. 165 / Friday, August 24, 2012 / Notices
received. Pursuant to the OMB
regulations, 5 CFR Part 1320, that
implement the PRA, 44 U.S.C. 3501 et
seq., the FTC is providing this second
opportunity for public comment while
seeking OMB approval to renew the preexisting clearance for the Rule. For more
details about the Rule requirements and
the basis for the calculations
summarized below, see 77 FR 31612.
Estimated Annual Burden: 100 hours
per breach (to determine what
information has been breached, identify
the affected customers, prepare the
breach notice, and make the required
report to the Commission) + 192 hours
to process an estimated 500 calls in the
event of a data breach.
Estimated Frequency: 2 breach
incidents.
Total Annual Labor Cost: $13,379.
Total Annual Capital or Other NonLabor Cost: $7,918.
Request For Comment:
You can file a comment online or on
paper. For the Commission to consider
your comment, we must receive it on or
before September 24, 2012. Write
‘‘Health Breach Notification Rule, PRA
Comments, P–125402’’ on your
comment. Your comment—including
your name and your state—will be
placed on the public record of this
proceeding, including to the extent
practicable, on the public Commission
Web site, at https://www.ftc.gov/os/
publiccomments.shtm. As a matter of
discretion, the Commission tries to
remove individuals’ home contact
information from comments before
placing them on the Commission Web
site.
Because your comment will be made
public, you are solely responsible for
making sure that your comment does
not include any sensitive personal
information, like anyone’s Social
Security number, date of birth, driver’s
license number or other state
identification number or foreign country
equivalent, passport number, financial
account number, or credit or debit card
number. You are also solely responsible
for making sure that your comment does
not include any sensitive health
information, like medical records or
other individually identifiable health
information. In addition, do not include
any ‘‘[t]rade secret or any commercial or
financial information which is * * *
privileged or confidential’’ as provided
in Section 6(f) of the FTC Act, 15 U.S.C.
46(f), and FTC Rule 4.10(a)(2), 16 CFR
4.10(a)(2). In particular, do not include
competitively sensitive information
such as costs, sales statistics,
inventories, formulas, patterns, devices,
manufacturing processes, or customer
names.
VerDate Mar<15>2010
15:22 Aug 23, 2012
Jkt 226001
If you want the Commission to give
your comment confidential treatment,
you must file it in paper form, with a
request for confidential treatment, and
you have to follow the procedure
explained in FTC Rule 4.9(c).2 Your
comment will be kept confidential only
if the FTC General Counsel, in his or her
sole discretion, grants your request in
accordance with the law and the public
interest.
Postal mail addressed to the
Commission is subject to delay due to
heightened security screening. As a
result, we encourage you to submit your
comments online. To make sure that the
Commission considers your online
comment, you must file it at https://
ftcpublic.commentworks.com/ftc/
healthbreachnotificationPRA2, by
following the instructions on the webbased form. If this Notice appears at
https://www.regulations.gov/#!home, you
also may file a comment through that
Web site.
If you file your comment on paper,
write ‘‘Health Breach Notification Rule,
PRA comments, P–125402’’ on your
comment and on the envelope, and mail
or deliver it to the following address:
Federal Trade Commission, Office of the
Secretary, Room H–113 (Annex J), 600
Pennsylvania Avenue NW., Washington,
DC 20580. If possible, submit your
paper comment to the Commission by
courier or overnight service.
Visit the Commission Web site at
https://www.ftc.gov to read this Notice
and the news release describing it. The
FTC Act and other laws that the
Commission administers permit the
collection of public comments to
consider and use in this proceeding as
appropriate. The Commission will
consider all timely and responsive
public comments that it receives on or
before September 24, 2012. You can find
more information, including routine
uses permitted by the Privacy Act, in
the Commission’s privacy policy, at
https://www.ftc.gov/ftc/privacy.htm.
Comments on the disclosure and
reporting requirements subject to review
under the PRA should additionally be
submitted to OMB. If sent by U.S. mail,
they should be addressed to Office of
Information and Regulatory Affairs,
Office of Management and Budget,
Attention: Desk Officer for the Federal
Trade Commission, New Executive
Office Building, Docket Library, Room
10102, 725 17th Street NW.,
Washington, DC 20503. Comments sent
2 In particular, the written request for confidential
treatment that accompanies the comment must
include the factual and legal basis for the request,
and must identify the specific portions of the
comment to be withheld from the public record. See
FTC Rule 4.9(c), 16 CFR 4.9(c).
PO 00000
Frm 00026
Fmt 4703
Sfmt 4703
to OMB by U.S. postal mail, however,
are subject to delays due to heightened
security precautions. Thus, comments
instead should be sent by facsimile to
(202) 395–5167.
Willard K. Tom,
General Counsel.
[FR Doc. 2012–20909 Filed 8–23–12; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the National Vaccine
Advisory Committee
Department of Health and
Human Services, Office of the Secretary,
Office of the Assistant Secretary for
Health.
ACTION: Notice of meeting.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the
Department of Health and Human
Services (HHS) is hereby giving notice
that the National Vaccine Advisory
Committee (NVAC) will hold a meeting.
The meeting is open to the public. Preregistration is required for both public
attendance and comment. Individuals
who wish to attend the meeting and/or
participate in the public comment
session should register at https://
www.hhs.gov/nvpo/nvac, email
nvpo@hhs.gov or call 202–690–5566 and
provide name, organization, and email
address.
SUMMARY:
The meeting will be held on
September 11–12, 2012. The meeting
times and agenda will be posted on the
NVAC Web site at https://www.hhs.gov/
nvpo/nvac as soon they become
available.
DATES:
U.S. Department of Health
and Human Services, Hubert H.
Humphrey Building, Room 800, 200
Independence Avenue SW.,
Washington, DC 20201.
FOR FURTHER INFORMATION CONTACT:
National Vaccine Program Office, U.S.
Department of Health and Human
Services, Room 715–H, Hubert H.
Humphrey Building, 200 Independence
Avenue SW., Washington, DC 20201.
Phone: (202) 690–5566; Fax: (202) 690–
4631; email: nvpo@hhs.gov.
SUPPLEMENTARY INFORMATION: Pursuant
to Section 2101 of the Public Health
Service Act (42 U.S.C. 300aa–1), the
Secretary of Health and Human Services
was mandated to establish the National
Vaccine Program to achieve optimal
prevention of human infectious diseases
through immunization and to achieve
optimal prevention against adverse
ADDRESSES:
E:\FR\FM\24AUN1.SGM
24AUN1
Federal Register / Vol. 77, No. 165 / Friday, August 24, 2012 / Notices
reactions to vaccines. The National
Vaccine Advisory Committee was
established to provide advice and make
recommendations to the Director of the
National Vaccine Program on matters
related to the Program’s responsibilities.
The Assistant Secretary for Health
serves as Director of the National
Vaccine Program.
Among the topics to be discussed at
the NVAC meeting are: Implementation
of the National Vaccine Plan, pertussis,
immunizations and health information
technology, Healthy People 2020,
immunization goals, and vaccine
hesitancy. The meeting agenda will be
posted on the NVAC Web site: https://
www.hhs.gov/nvpo/nvac prior to the
meeting.
Public attendance at the meeting is
limited to space available. Individuals
who plan to attend and need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify the
National Vaccine Program Office at the
address/phone listed above at least one
week prior to the meeting. Members of
the public will have the opportunity to
provide comments at the NVAC meeting
during the public comment periods on
the agenda. Individuals who would like
to submit written statements should
email or fax their comments to the
National Vaccine Program Office at least
five business days prior to the meeting.
Dated: August 21, 2012.
Bruce Gellin,
Director, National Vaccine Program Office,
Executive Secretary, National Vaccine
Advisory Committee.
[FR Doc. 2012–20910 Filed 8–23–12; 8:45 am]
BILLING CODE 4150–44–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meetings of the National Biodefense
Science Board
Department of Health and
Human Services, Office of the Secretary.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Services is hereby giving notice that the
National Biodefense Science Board
(NBSB) will be holding a closed session
under exemption 9(B) of the
Government in Sunshine Act, 5 U.S.C.
section 552b(c).
DATES: The closed session of the NBSB
will take place on September 17, 2012,
and is tentatively scheduled from 1:30
p.m. to 3:30 p.m. EST. The agenda and
time for the session are subject to
erowe on DSK2VPTVN1PROD with
SUMMARY:
VerDate Mar<15>2010
15:22 Aug 23, 2012
Jkt 226001
change as priorities dictate. Please
check the NBSB Web site for the most
up-to-date information.
The closed session will be
held by teleconference and/or webinar
and will not be open to the public as
stipulated under exemption 9(B) of the
Government in Sunshine Act, 5 U.S.C.
section 552b(c).
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
The
National Biodefense Science Board
mailbox: NBSB@HHS.GOV.
Pursuant
to section 319M of the Public Health
Service Act (42 U.S.C. 247d–7f) and
section 222 of the Public Health Service
Act (42 U.S.C. 217a), the Department of
Health and Human Services established
the National Biodefense Science Board.
The Board shall provide expert advice
and guidance to the Secretary on
scientific, technical, and other matters
of special interest to the Department of
Health and Human Services (HHS)
regarding current and future chemical,
biological, nuclear, and radiological
agents, whether naturally occurring,
accidental, or deliberate. The Board may
also provide advice and guidance to the
Secretary and/or the Assistant Secretary
for Preparedness and Response (ASPR)
on other matters related to public health
emergency preparedness and response.
Background: The NBSB continues to
review and evaluate the 2012 Public
Health Emergency Medical
Countermeasures Enterprise (PHEMCE)
Strategy and Implementation Plan (SIP).
Therefore, the Board’s deliberations on
the PHEMCE SIP task are being
conducted in closed sessions in
accordance with provisions set forth
under exemption 9(B) of the
Government in Sunshine Act, 5 U.S.C.
section 552b(c), and with approval by
the ASPR. For a full description for the
basis for closing this session, please see
the previous meeting notice published
at 77 FR 13129 (2012).
Availability of Materials: The meeting
agenda and materials will be posted on
the NBSB Web site at www.PHE.GOV/
NBSB.
Procedures for Providing Public Input:
All written comments should be sent by
email to NBSB@HHS.GOV with ‘‘NBSB
Public Comment’’ as the subject line.
SUPPLEMENTARY INFORMATION:
Dated: August 20, 2012.
Nicole Lurie,
Assistant Secretary for Preparedness and
Response.
[FR Doc. 2012–20930 Filed 8–23–12; 8:45 am]
BILLING CODE 4150–37–P
PO 00000
Frm 00027
Fmt 4703
Sfmt 4703
51537
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–3258–FN]
Medicare and Medicaid Programs;
Continued Approval of Det Norske
Veritas Healthcare’s (DNVHC’s)
Hospital Accreditation Program
Centers for Medicare and
Medicaid Services, HHS.
ACTION: Final notice.
AGENCY:
This final notice announces
our decision to approve the Det Norske
Veritas Healthcare (DNVHC) for
continued recognition as a national
accrediting organization for hospitals
that wish to participate in the Medicare
or Medicaid programs. A hospital that
participates in Medicaid must also meet
the Medicare conditions of participation
as referenced in 42 CFR 488.5(3)(b) and
42 CFR 488.6(b). This approval is
effective September 26, 2012, through
September 26, 2018.
DATES: This final notice is effective
September 26, 2012, through September
26, 2018.
FOR FURTHER INFORMATION CONTACT:
Barbara Easterling, (410) 786–0482;
Cindy Melanson, (410) 786–0310; or
Patricia Chmielewski, (410) 786–6899.
SUPPLEMENTARY INFORMATION:
SUMMARY:
I. Background
Under the Medicare program, eligible
beneficiaries may receive covered
services in a hospital provided certain
requirements are met. Section 1861(e) of
the Social Security Act (the Act)
establishes distinct criteria for facilities
seeking designation as a hospital.
Regulations concerning provider
agreements are at 42 CFR part 489 and
those pertaining to activities relating to
the survey and certification of facilities
are at part 488. The regulations at part
482 specify the conditions that a
hospital must meet to participate in the
Medicare program, the scope of covered
services and the conditions for Medicare
payment for hospitals.
Generally, to enter into an agreement,
a hospital must first be certified by a
state survey agency as complying with
the conditions or requirements set forth
in part 482. Thereafter, the hospital is
subject to regular surveys by a state
survey agency to determine whether it
continues to meet these requirements.
However, there is an alternative to
surveys by state agencies. Certification
by a nationally recognized accreditation
program can substitute for ongoing state
review.
E:\FR\FM\24AUN1.SGM
24AUN1
]]>Agencies
[Federal Register Volume 77, Number 165 (Friday, August 24, 2012)]
[Notices]
[Pages 51536-51537]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-20910]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the National Vaccine Advisory Committee
AGENCY: Department of Health and Human Services, Office of the
Secretary, Office of the Assistant Secretary for Health.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the
Department of Health and Human Services (HHS) is hereby giving notice
that the National Vaccine Advisory Committee (NVAC) will hold a
meeting. The meeting is open to the public. Pre-registration is
required for both public attendance and comment. Individuals who wish
to attend the meeting and/or participate in the public comment session
should register at https://www.hhs.gov/nvpo/nvac, email nvpo@hhs.gov or
call 202-690-5566 and provide name, organization, and email address.
DATES: The meeting will be held on September 11-12, 2012. The meeting
times and agenda will be posted on the NVAC Web site at https://www.hhs.gov/nvpo/nvac as soon they become available.
ADDRESSES: U.S. Department of Health and Human Services, Hubert H.
Humphrey Building, Room 800, 200 Independence Avenue SW., Washington,
DC 20201.
FOR FURTHER INFORMATION CONTACT: National Vaccine Program Office, U.S.
Department of Health and Human Services, Room 715-H, Hubert H. Humphrey
Building, 200 Independence Avenue SW., Washington, DC 20201. Phone:
(202) 690-5566; Fax: (202) 690-4631; email: nvpo@hhs.gov.
SUPPLEMENTARY INFORMATION: Pursuant to Section 2101 of the Public
Health Service Act (42 U.S.C. 300aa-1), the Secretary of Health and
Human Services was mandated to establish the National Vaccine Program
to achieve optimal prevention of human infectious diseases through
immunization and to achieve optimal prevention against adverse
[[Page 51537]]
reactions to vaccines. The National Vaccine Advisory Committee was
established to provide advice and make recommendations to the Director
of the National Vaccine Program on matters related to the Program's
responsibilities. The Assistant Secretary for Health serves as Director
of the National Vaccine Program.
Among the topics to be discussed at the NVAC meeting are:
Implementation of the National Vaccine Plan, pertussis, immunizations
and health information technology, Healthy People 2020, immunization
goals, and vaccine hesitancy. The meeting agenda will be posted on the
NVAC Web site: https://www.hhs.gov/nvpo/nvac prior to the meeting.
Public attendance at the meeting is limited to space available.
Individuals who plan to attend and need special assistance, such as
sign language interpretation or other reasonable accommodations, should
notify the National Vaccine Program Office at the address/phone listed
above at least one week prior to the meeting. Members of the public
will have the opportunity to provide comments at the NVAC meeting
during the public comment periods on the agenda. Individuals who would
like to submit written statements should email or fax their comments to
the National Vaccine Program Office at least five business days prior
to the meeting.
Dated: August 21, 2012.
Bruce Gellin,
Director, National Vaccine Program Office, Executive Secretary,
National Vaccine Advisory Committee.
[FR Doc. 2012-20910 Filed 8-23-12; 8:45 am]
BILLING CODE 4150-44-P
